Douglas Williams, Ph.D., will leave Biogen at the end of July to become CEO of as-yet unnamed start-up biotechnology company. Dr. Williams will be the first member of a new organization with potential in cancer diagnostics and therapy. Responsibility for Biogen Research and Development will be assumed by Alfred Sandrock, M.D., Ph.D., senior vice president […]
News: Douglas Williams Leaving Biogen $BIIB Read More »
European Medicines Agency has approved the Marketing Authorization Application of ALPROLIX by Biogen and Sobi. ALPROLIX, a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. According to MAA, Phase 3 Trials for Efficacy, safety and pharmacokinetics tests would be done. Biogen and Sobi are collaborators in the development and commercialization
News: EMA Approves ALPROLIX Marketing $BIIB Read More »
Biogen Inc. has announced its first quarter results for FY-2015. The Results shows the following:- Quarterly Revenues up by 20% now at $2.6 Billion, EPS was $3.49 up by 73% Y/Y. View the full earnings release here.
Biogen Earnings on Rise $BIIB $XHS Read More »
